

WHO Expert Committee on Biological Standardization

Seventy-fifth report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland; email: bookorders@who.int; order online: <http://apps.who.int/bookorders>.

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 4 3

WHO Expert Committee on Biological Standardization

Seventy-fifth report

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Expert Committee on Biological Standardization: seventy-fifth report

(WHO Technical Report Series, No. 1043)

ISBN 978-92-4-005708-1 (electronic version)

ISBN 978-92-4-005709-8 (print version)

ISSN 0512-3054

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO Expert Committee on Biological Standardization: seventy-fifth report. Geneva: World Health Organization; 2022 (WHO Technical Report Series, No. 1043). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout by Interligar

Contents

Abbreviations	xi
1. Introduction	1
2. General	4
2.1 Strategic directions in biological standardization	4
2.1.1 COVID-19 standardization: lessons learnt and vision for the future	4
2.1.2 Priorities in the development or revision of WHO written standards	6
2.1.3 Update on the 3Rs project	7
3. International Recommendations, Guidelines and other matters related to the manufacture, quality control and evaluation of biological products	10
3.1 General	10
3.1.1 WHO manual for the preparation of reference materials for use as secondary standards in antibody testing	10
3.2 Biotherapeutics other than blood products	11
3.2.1 Guidelines on evaluation of biosimilars	11
3.2.2 Guidelines for the production and quality control of monoclonal antibodies and related products intended for medicinal use	14
4. International reference materials – cell and gene therapy products	16
4.1 Proposed new projects and updates – cell and gene therapy products	16
4.1.1 Proposed changes to the First WHO International Reference Panel for lentiviral vector integration copy number	16
5. International reference materials – in vitro diagnostics	18
5.1 WHO international reference standards for in vitro diagnostics	18
5.1.1 WHO International Reference Reagent for anti-human neutrophil antigen-3a immunoglobulin G	18
5.1.2 First WHO International Standard for Lassa virus RNA for NAT-based assays; and First WHO International Reference Panel for Lassa virus RNA for NAT-based assays	19
5.1.3 First WHO International Standard for anti-β2GPI immunoglobulin G	21
5.2 Proposed new projects and updates – in vitro diagnostics	23
5.2.1 Proposed WHO international reference reagents for anti-human leukocyte antigen antibodies	23
6. International reference materials – standards for use in high-throughput sequencing technologies	26
6.1 WHO international reference standards for use in high-throughput sequencing technologies	26
6.1.1 WHO international reference reagents for gut microbiome analysis	26
7. International reference materials – standards for use in public health emergencies	28
7.1 Proposed new projects and updates – standards for use in public health emergencies	28

7.1.1	Update on the development of the First WHO International Standard for SARS-CoV-2 antigen	28
7.1.2	Update on the development of the Second WHO International Standard for anti-SARS-CoV-2 immunoglobulin; and First WHO International Reference Panel for antibodies to SARS-CoV-2 variants of concern	29
8.	International reference materials – vaccines and related substances	31
8.1	WHO international reference standards for vaccines and related substances	31
8.1.1	First WHO International Standard for anti-enterovirus D68 serum (human)	31
8.2	Proposed new projects and updates – vaccines and related substances	32
8.2.1	Proposed WHO international reference reagents for non-endotoxin pyrogens	32
8.2.2	Update on the development of WHO international standards for antibodies against human papillomavirus types 6, 11, 31, 33, 45, 52 and 58	33
Annex 1		
	WHO Recommendations, Guidelines and other documents related to the manufacture, quality control and evaluation of biological products	35
Annex 2		
	WHO manual for the preparation of reference materials for use as secondary standards in antibody testing	41
Annex 3		
	Guidelines on evaluation of biosimilars	
	Replacement of Annex 2 of WHO Technical Report Series, No. 977	131
Annex 4		
	Guidelines for the production and quality control of monoclonal antibodies and related products intended for medicinal use	
	Replacement of Annex 3 of WHO Technical Report Series, No. 822	183
Annex 5		
	New and replacement WHO international reference standards for biological products	251

WHO Expert Committee on Biological Standardization

Seventy-fifth meeting held virtually 4 to 8 April 2022

Committee members¹

Dr P. Aprea, National Administration of Drugs, Food and Medical Technology, Buenos Aires, Argentina

Dr C. Burns, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom

Dr N. Choudhury, Assam Cancer Care Foundation, Dibrugarh, India

Professor K. Cichutek, Paul-Ehrlich-Institut, Langen, Germany (*Vice-chair*)

Dr M. Darko, Food and Drugs Authority, Accra, Ghana

Dr A.E. del Pozo, Hospital de Pediatría Garrahan, Buenos Aires, Argentina

Dr I. Feavers, Consultant, Nacton, the United Kingdom (*Rapporteur*)

Professor I. Fradi-Dridi, Direction de la Pharmacie et du Médicament, Tunis, Tunisia

Professor S. Hindawi, King Abdulaziz University, Jeddah, Saudi Arabia (*Vice-chair*)

Mrs T. Jivapaisarnpong, Advisor, King Mongkut's University of Technology Thonburi, Bangkok, Thailand

Dr N.G. Mahlangu, Regulatory Consultant, Harare, Zimbabwe

Dr R. May,² Dubai Health Authority, Dubai, United Arab Emirates

Ms C. Morris, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom

Professor D.H. Muljono, Hasanuddin University, Makassar, Indonesia

Mr V.R. Reddy,² South African National Blood Service, Weltevreden Park, South Africa

Dr Y. Sohn, Seoul National University, Seoul, Republic of Korea

Dr J. Southern, Representative of the South African Health Products Regulatory Authority, Simon's Town, South Africa

Dr P. Strengers, Consultant, Amsterdam, Netherlands

Dr D. Teo, Visiting Consultant, Blood Services Group, Health Sciences Authority, Singapore, Singapore (*Co-rapporteur*)

¹ The decisions of the Committee were taken in closed session with only members of the Committee and WHO Secretariat present. Each Committee member had completed a Declaration of Interests form prior to the meeting. These were assessed by the WHO Secretariat and no declared interests were considered to be in conflict with full meeting participation.

² Unable to attend.

Dr J. Wang, National Institutes for Food and Drug Control, Beijing, China

Dr Y. Wang, National Institutes for Food and Drug Control, Beijing, China

Dr S. Wendel, Hospital Sirio-Libanês, São Paulo, Brazil

Dr C. Witten, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States of America (the USA) (*Chair*)

Temporary advisors

Dr K.M. Boukef, University of Monastir, Monastir, Tunisia

Dr N. Ekman, Finnish Medicines Agency, Helsinki, Finland

Dr E. Griffiths, Kingston upon Thames, the United Kingdom

Dr H-K Heim, Federal Institute for Drugs and Medical Devices, Bonn, Germany

Dr A. Hilger, Paul-Ehrlich-Institut, Langen, Germany

Dr A. Holmes, National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs), London, the United Kingdom

Dr S. Hufton, National Institute for Biological Standards and Control, Potters Bar, the United Kingdom

Dr G. Kang,³ Christian Medical College, Vellore, India

Dr M. Koh, St George's Hospital, London, the United Kingdom

Dr O. Kolaj-Robin, European Directorate for the Quality of Medicines & Healthcare, Strasbourg, France

Dr P. Kurki, University of Helsinki, Helsinki, Finland

Dr E. Lacana, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD, the USA

Dr E. Lilley, National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) London the United Kingdom

3, 2022

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31672

